Structure Elucidation, Biosynthetic Gene Cluster Distribution, and Biological Activities of Ketomemicin Analogs in Salinispora

Gabriel Castro‐Falcón, Dulce G. Guillén Matus, Elany Barbosa da Silva, Wentao Guo, Alicia Ross, Mateus Sá Magalhães Serafim, Thaís Helena Maciel Fernandes, Dean J. Tantillo, Anthony J. O’Donoghue, Paul R. JensenMarine 2025 · DOI

TL;DR

This paper identifies three new ketomemicin pseudopeptides from the marine bacterium Salinispora pacifica, elucidates their structures, and investigates the distribution of their biosynthetic gene cluster across the Salinispora genus and related bacteria. The study also reveals moderate protease inhibitory activity for one of the new compounds, highlighting the potential of these marine microbes for discovering novel bioactive molecules.

What Problem Does This Paper Address?

The discovery of novel natural products with therapeutic potential is a continuous challenge. Pseudopeptides, a class of molecules mimicking natural peptide substrates but with enhanced stability, are particularly interesting as protease inhibitors. While ketomemicins and related arphamenines are known pseudopeptides with this activity, their production and biosynthetic pathways, especially in marine actinomycetes like Salinispora, have not been fully explored. This paper addresses the gap in understanding ketomemicin diversity, their production by Salinispora, and the genetic basis for their biosynthesis, aiming to uncover new analogs and their biological activities.

Methods

The researchers employed a multi-pronged approach:

  • Isolation and Structure Elucidation: Standard techniques like HPLC-MS and preparative HPLC were used to isolate the new compounds. Structure elucidation relied on a combination of High-Resolution Mass Spectrometry (HRMS) for molecular formulas and extensive 1D and 2D Nuclear Magnetic Resonance (NMR) spectroscopy (including ¹H, ¹³C, HSQC, HMBC, and COSY) to determine connectivity. Quantum chemical calculations and DP4+ analysis were crucial for assigning the relative stereochemistry of the complex molecules.
  • Bioinformatic Analysis: Molecular networking using the Global Natural Products Social Molecular Networking (GNPS) platform was employed to identify known and related compounds in existing datasets. This was complemented by searching public Salinispora metabolomic datasets and genome sequences. AntiSMASH and Cblaster tools were used to identify and analyze biosynthetic gene clusters (BGCs).
  • Biological Activity Testing: The isolated ketomemicins were tested against a panel of eleven proteases using standard enzyme inhibition assays.

Datasets

  • Public Salinispora LC-MS/MS Datasets: Used for molecular networking and identification of known ketomemicin analogs. Specifically, datasets from Crüsemann et al. (2017) were utilized.
  • Public Salinispora Genome Sequences: 118 publicly available genomes were analyzed to assess the distribution of the ketomemicin biosynthetic gene cluster (ktm BGC).
  • NCBI Genome Database: Queried to identify ktm homologs in non-Salinispora Actinomycetota.

Key Insights and Ideas

  • Novel Ketomemicin Structures: The discovery of three new ketomemicin analogs (1-3) expands the known chemical diversity within this pseudopeptide class.
  • Broad but Inconsistent Production: Ketomemicin production is widespread across the Salinispora genus, with the ktm BGC being highly conserved. However, not all strains possessing the BGC actually produce the compounds, suggesting complex regulatory mechanisms or potential non-functionality in some cases.
  • Evolutionary Significance of the ktm BGC: The high synteny of the ktm BGC across Salinispora species, and its phylogenetic congruence with the species phylogeny, strongly suggests vertical inheritance from a common ancestor. The acquisition of the BGC by S. oceanensis from S. pacifica highlights potential horizontal gene transfer events.
  • Potential for New Analogs Beyond Salinispora: The identification of ktm homologs in other bacterial genera indicates a broader potential for discovering novel ketomemicin-like compounds in the Actinomycetota phylum.
  • Structure-Activity Relationship Hints: Compound 2 showed moderate inhibition against SARS-CoV-1, SARS-CoV-2, and MERS-CoV main proteases, providing initial insights into the biological activity of these novel analogs and their potential as antiviral agents.

Key Results

  • Three new ketomemicin pseudopeptides (1–3) were isolated and structurally elucidated.
  • Five additional ketomemicin analogs (4–8) were identified from existing metabolomic datasets.
  • The ktm BGC was found in 79 out of 118 Salinispora genomes, present in eight of nine named species.
  • Ketomemicin production was detected in 25 of 118 Salinispora strains.
  • Compound 2 exhibited moderate inhibitory activity against SARS-CoV-1, SARS-CoV-2, and MERS-CoV main proteases at 10 µM.
  • ktm homologs were identified in 28 non-Salinispora Actinomycetota.

Limitations and Future Work

  • Absolute Stereochemistry: The absolute stereochemistry of the newly identified ketomemicins could not be determined due to the challenges associated with their hydrolysis and derivatization for standard methods like Marfey's.
  • Non-Producing BGC Strains: The reason why some Salinispora strains with a complete ktm BGC do not produce ketomemicins remains unclear. Further investigation into regulatory mechanisms or potential BGC dormancy is warranted.
  • Broader Protease Inhibition: While compound 2 showed some activity, a more comprehensive screening against a wider range of proteases and at different concentrations could reveal more potent inhibitors.
  • Characterization of Non-Salinispora Analogs: The identified ktm homologs in other bacterial genera represent an opportunity to discover novel ketomemicin variants with potentially different structures and activities. Future work could focus on heterologous expression or targeted isolation from these organisms.

Summary updated

Abstract

Pseudopeptides are attractive agents for protease inhibition due to their structural similarities to the natural substrates of these enzymes, as well as their enhanced stability and resistance to enzymatic degradation. We report three new ketomemicin pseudopeptides (<b>1</b>-<b>3</b>) from extracts of the marine actinomycete <i>Salinispora pacifica</i> strain CNY-498. Their constitution and relative configuration were elucidated using NMR, mass spectrometry, and quantum chemical calculations. Using GNPS molecular networking and publicly available <i>Salinispora</i> LCMS datasets, five additional ketomemicin analogs (<b>4</b>-<b>8</b>) were identified with ketomemicin production detected broadly across <i>Salinispora</i> species. The ketomemicin biosynthetic gene cluster (<i>ktm</i>) is highly conserved in <i>Salinispora</i>, occurring in 79 of 118 public genome sequences, including eight of the nine named species. Outside <i>Salinispora</i>, <i>ktm</i> homologs were detected in various genera of the phylum Actinomycetota that might encode novel ketomemicin analogs. Ketomemicins <b>1</b>-<b>3</b> were tested against a panel of eleven proteases, with <b>2</b> displaying moderate inhibitory activity. This study describes the first report of ketomemicin production by <i>Salinispora</i> cultures, the distribution of the corresponding biosynthetic gene cluster, and the protease inhibitory activity of new ketomemicin derivatives.
BibTeX
@inproceedings{castrofalcon2025structure,
  author = {Gabriel Castro‐Falcón and Dulce G. Guillén Matus and Elany Barbosa da Silva and Wentao Guo and Alicia Ross and Mateus Sá Magalhães Serafim and Thaís Helena Maciel Fernandes and Dean J. Tantillo and Anthony J. O’Donoghue and Paul R. Jensen},
  title = {{Structure Elucidation, Biosynthetic Gene Cluster Distribution, and Biological Activities of Ketomemicin Analogs in Salinispora}},
  booktitle = {Marine},
  year = {2025},
  doi = {10.3390/md23030126},
}
Figure